Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 8/20 | 0.62 |
| ▸ | NPC1 | O15118 | 7/20 | 0.62 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.62 |
| ▸ | MEN1 | O00255 | 4/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.62 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.60 |
| ▸ | HTT | P42858 | 2/20 | 0.60 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.60 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.60 |
| ▸ | RELA | Q04206 | 1/20 | 0.60 |
| ▸ | CASP3 | P42574 | 5/20 | 0.57 |
| ▸ | SENP8 | Q96LD8 | 5/20 | 0.57 |
| ▸ | SENP7 | Q9BQF6 | 5/20 | 0.57 |
| ▸ | SENP6 | Q9GZR1 | 5/20 | 0.57 |
| ▸ | SCD | O00767 | 3/20 | 0.57 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.57 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.57 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.57 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.57 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3049831 | 0.80 | RAB9A (0.77) | RAB9ANPC1SMN1; SMN2MEN1KMT2A | |
| SCHEMBL19270384 | 0.78 | RAB9A (0.47) | RAB9ANPC1SMN1; SMN2MEN1KMT2A | |
| SCHEMBL5732234 | 0.77 | NPC1 (0.70) | RAB9ANPC1SMN1; SMN2MEN1KMT2A | |
| SCHEMBL3053529 | 0.77 | NPC1 (1.00) | RAB9ANPC1SMN1; SMN2MEN1KMT2A | |
| SCHEMBL2245324 | 0.76 | CSNK2A2 (0.74) | RAB9ANPC1SMN1; SMN2MEN1KMT2A | |
| SCHEMBL6226995 | 0.76 | NPC1 (0.81) | RAB9ANPC1SMN1; SMN2MEN1KMT2A | |
| SCHEMBL6229312 | 0.76 | NPC1 (0.76) | RAB9ANPC1SMN1; SMN2MEN1KMT2A | |
| SCHEMBL19253628 | 0.76 | ABL1 (0.43) | RAB9ANPC1SMN1; SMN2MEN1KMT2A | |
| SCHEMBL32674581 | 0.76 | NPC1 (0.84) | RAB9ANPC1SMN1; SMN2MEN1KMT2A | |
| SCHEMBL27634788 | 0.76 | NPC1 (0.84) | RAB9ANPC1SMN1; SMN2MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1599468-A1 | 1,2,3-TRISUBSTITUTED ARYL AND HETEROARYL DERIVATIVES AS MODULATORS OF METABOLISM AND THE PROPHYLAXIS AND TREATMENT OF DISORDERS RELATED THERETO SUCH AS DIABETES AND HYPERGLYCEMIA | Arena Pharmaceuticals, Inc. (US) | 2005-11-30 | — | — | EP | claimed |
| WO-2004065380-A1 | 1,2,3-TRISUBSTITUTED ARYL AND HETEROARYL DERIVATIVES AS MODULATORS OF METABOLISM AND THE PRPPHYLAXIS AND TREATMENT OF DISORDERS RELATED THERETO SUCH AS DIABETES AND HYPERGLYCEMIA | ARENA PHARMACEUTICALS INC. (US) | 2004-08-05 | — | — | WO | claimed |
| US-20230382903-A1 | SMALL MOLECULE MODULATORS OF GP130 SIGNALING PATHWAYS, TOPICAL FORMULATIONS AND METHOD OF USE THEREOF | CARTHRONIX INC (US) | 2023-11-30 | — | — | US | disclosed |
| US-20230382903-A1 | SMALL MOLECULE MODULATORS OF GP130 SIGNALING PATHWAYS, TOPICAL FORMULATIONS AND METHOD OF USE THEREOF | CARTHRONIX INC (US) | 2023-11-30 | — | — | US | disclosed |
| US-11420964-B2 | Compositions and methods for modulating inflammatory and degenerative disorder | UNIVERSITY OF SOUTHERN CALIFORNIA (US) | 2022-08-23 | — | — | US | disclosed |
| WO-2022082071-A1 | SMALL MOLECULE MODULATORS OF GP130 SIGNALING PATHWAYS, TOPICAL FORMULATIONS AND METHOD OF US THEREOF | CARTHRONIX, INC. (US) | 2022-04-21 | — | — | WO | disclosed |
| US-20220048901-A1 | COMPOSITIONS AND METHODS FOR MODULATING INFLAMMATORY AND DEGENERATIVE DISORDER | UNIVERSITY OF SOUTHERN CALIFORNIA | 2022-02-17 | — | — | US | disclosed |
| US-20200377494-A1 | COMPOSITIONS AND METHODS FOR MODULATING INFLAMMATORY AND DEGENERATIVE DISORDER | UNIVERSITY OF SOUTHERN CALIFORNIA | 2020-12-03 | — | — | US | disclosed |
| EP-1599468-A1 | 1,2,3-TRISUBSTITUTED ARYL AND HETEROARYL DERIVATIVES AS MODULATORS OF METABOLISM AND THE PROPHYLAXIS AND TREATMENT OF DISORDERS RELATED THERETO SUCH AS DIABETES AND HYPERGLYCEMIA | Arena Pharmaceuticals, Inc. (US) | 2005-11-30 | — | — | EP | disclosed |
| WO-2004065380-A1 | 1,2,3-TRISUBSTITUTED ARYL AND HETEROARYL DERIVATIVES AS MODULATORS OF METABOLISM AND THE PRPPHYLAXIS AND TREATMENT OF DISORDERS RELATED THERETO SUCH AS DIABETES AND HYPERGLYCEMIA | ARENA PHARMACEUTICALS INC. (US) | 2004-08-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230382903-A1 | SMALL MOLECULE MODULATORS OF GP130 SIGNALING PATHWAYS, TOPICAL FORMULATIONS AND METHOD OF USE THEREOF | STAT1, STAT3, STAT6 | RAB9A 3504/4885NPC1 2133/4885SMN1; SMN2 4696/4885 |
| US-11420964-B2 | Compositions and methods for modulating inflammatory and degenerative disorder | TNF, MSR1, GRN | RAB9A 2595/4885NPC1 1571/4885SMN1; SMN2 1011/4885 |
| US-20220048901-A1 | COMPOSITIONS AND METHODS FOR MODULATING INFLAMMATORY AND DEGENERATIVE DISORDER | TNF, MSR1, GRN | RAB9A 2595/4885NPC1 1571/4885SMN1; SMN2 1011/4885 |
| US-20200377494-A1 | COMPOSITIONS AND METHODS FOR MODULATING INFLAMMATORY AND DEGENERATIVE DISORDER | TNF, MSR1, GRN | RAB9A 2595/4885NPC1 1571/4885SMN1; SMN2 1011/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.